---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-292953"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2022-11-28T23:59:59+00:00"
generated_at: "2026-06-21T12:50:21.684277+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology nominates IK-595 as first RAS pathway candidate; IND targeted H2 2023

## Summary
- IK-595: MEK-RAF complex inhibitor traps MEK & RAF in inactive complex, aims to avoid resistance.
- Discontinuing IK-007 (EP4 antagonist) internal development; exploring strategic alternatives.
- Cash runway extended into 2025; does not include potential IK-175 opt-in fees from BMS.
- IK-930 TEAD inhibitor monotherapy initial clinical data expected H2 2023; osimertinib combo starts H1 2023.
- Preclinical differentiation data for IK-595 planned for H1 2023; RAS pathway implicated in >500K US cancer cases/yr.

## SEC filing metadata
- accession: 0001193125-22-292953
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2022-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312522292953/0001193125-22-292953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312522292953/d420821d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-292953
- JSON: https://secwatch.observer/filing/0001193125-22-292953.json
- Plain text: https://secwatch.observer/filing/0001193125-22-292953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.